| Characteristic | Alopecia N = 1921 |
Androgenetic alopecia N = 701 |
Benign prostatic hyperplasia N = 231 |
Other N = 531 |
Product used for unknown indication N = 791 |
|---|---|---|---|---|---|
| Age, years | 34.20 (9.22) | 29.65 (7.57) | 71.95 (7.38) | 59.33 (17.35) | 47.60 (21.26) |
| (Missing) | 29 | 2 | 3 | 7 | 26 |
| Weight, kilograms | 82.44 (18.18) | 81.26 (13.69) | 92.10 (23.20) | 83.16 (14.37) | 72.01 (23.00) |
| (Missing) | 94 | 19 | 4 | 10 | 57 |
| Time to Adverse Event | 39.95 (85.26) | 85.80 (129.38) | 113.11 (143.34) | 63.30 (71.59) | 22.22 (30.49) |
| (Missing) | 105 | 40 | 18 | 45 | 72 |
| Country | |||||
| Canada | 15 (11%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (6.3%) |
| European countries where Fin 1 mg is approved for AGA | 27 (19%) | 23 (51%) | 0 (0%) | 0 (0%) | 6 (7.6%) |
| Other | 18 (13%) | 4 (8.9%) | 0 (0%) | 7 (14%) | 15 (19%) |
| United Kingdom | 65 (46%) | 4 (8.9%) | 18 (95%) | 40 (82%) | 32 (41%) |
| United States of America | 17 (12%) | 14 (31%) | 1 (5.3%) | 2 (4.1%) | 21 (27%) |
| (Missing) | 50 | 25 | 4 | 4 | 0 |
| Reporter's occupation | |||||
| Consumer | 109 (77%) | 38 (57%) | 13 (93%) | 37 (93%) | 49 (72%) |
| Lawyer | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (4.4%) |
| Other Health Professional | 7 (5.0%) | 2 (3.0%) | 0 (0%) | 0 (0%) | 4 (5.9%) |
| Pharmacist | 5 (3.5%) | 0 (0%) | 1 (7.1%) | 1 (2.5%) | 4 (5.9%) |
| Physician | 20 (14%) | 27 (40%) | 0 (0%) | 2 (5.0%) | 8 (12%) |
| (Missing) | 51 | 3 | 9 | 13 | 11 |
| Dechallenge | |||||
| Does not apply | 26 (14%) | 25 (36%) | 0 (0%) | 4 (9.8%) | 2 (2.8%) |
| Negative dechallenge | 67 (36%) | 31 (44%) | 8 (67%) | 12 (29%) | 4 (5.6%) |
| Positive dechallenge | 76 (41%) | 10 (14%) | 0 (0%) | 7 (17%) | 9 (13%) |
| Unknown | 17 (9.1%) | 4 (5.7%) | 4 (33%) | 18 (44%) | 56 (79%) |
| (Missing) | 6 | 0 | 11 | 12 | 8 |
| Rechallenge | |||||
| Does not apply | 42 (50%) | 13 (50%) | 4 (57%) | 3 (21%) | 0 (0%) |
| Negative rechallenge | 1 (1.2%) | 2 (7.7%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Positive rechallenge | 5 (6.0%) | 10 (38%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Unknown | 36 (43%) | 1 (3.8%) | 3 (43%) | 11 (79%) | 40 (100%) |
| (Missing) | 108 | 44 | 16 | 39 | 39 |
| Sexual AE | |||||
| Erectile dysfunction | 71 (37%) | 22 (31%) | 10 (43%) | 28 (53%) | 32 (41%) |
| Libido decreased | 19 (9.9%) | 12 (17%) | 1 (4.3%) | 3 (5.7%) | 7 (8.9%) |
| Libido disorder | 4 (2.1%) | 1 (1.4%) | 1 (4.3%) | 0 (0%) | 3 (3.8%) |
| Loss of libido | 52 (27%) | 8 (11%) | 6 (26%) | 11 (21%) | 18 (23%) |
| Male sexual dysfunction | 5 (2.6%) | 1 (1.4%) | 0 (0%) | 1 (1.9%) | 1 (1.3%) |
| Organic erectile dysfunction | 2 (1.0%) | 1 (1.4%) | 1 (4.3%) | 1 (1.9%) | 0 (0%) |
| Penile pain | 1 (0.5%) | 2 (2.9%) | 0 (0%) | 1 (1.9%) | 1 (1.3%) |
| Penile size reduced | 3 (1.6%) | 4 (5.7%) | 1 (4.3%) | 0 (0%) | 1 (1.3%) |
| Sexual dysfunction | 24 (13%) | 7 (10%) | 3 (13%) | 5 (9.4%) | 13 (16%) |
| Testicular atrophy | 1 (0.5%) | 2 (2.9%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Testicular pain | 10 (5.2%) | 10 (14%) | 0 (0%) | 3 (5.7%) | 3 (3.8%) |
| 1 Mean (SD); n (%) | |||||